FDA advisers to weigh updated COVID vaccine targeting XFG subvariant
The Food and Drug Administration's (FDA) advisory committee on vaccines this week will consider whether to change the COVID-19 vaccine to target the XFG subvariant for the upcoming 2026-2027 respiratory viral season. The Vaccines and Related Biological Products Advisory Committee (VRBPAC) for the FDA will meet Thursday to discuss whether COVID-19 vaccines should target the…
The Food and Drug Administration's (FDA) advisory committee on vaccines this week will consider whether to change the COVID-19 vaccine to target the XFG subvariant for the upcoming 2026-2027 respiratory viral season. The Vaccines and Related Biological Products Advisory Committee (VRBPAC) for the FDA will meet Thursday to discuss whether COVID-19 vaccines should target the…
The Food and Drug Administration's (FDA) advisory committee on vaccines this week will consider whether to change the COVID-19 vaccine to target the XFG subvariant for the upcoming 2026-2027 respiratory viral season. The Vaccines and Related Biological Products Advisory Committee (VRBPAC) for the FDA will meet Thursday to discuss whether COVID-19 vaccines should target the…
The full story continues on The Hill.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.